Targeting RIPK3 to reduce heart damage after a heart attack
Official title: Mechanism and Therapeutic Targeting of RIPK3-Driven Cell Death in Reperfused Myocardial Infarction
Funded at Albert Einstein College of Medicine · NIH-11450795 · Data updated 2026-11-12
This grant studies a specific cell-death pathway (RIPK3) to protect the heart after a heart attack, with the goal of reducing damage and improving recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | August 10, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $862,509 |
| NIH project number | 1R01HL183440-01A1 |
| Project ID | NIH-11450795 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21+ who have or are at risk for myocardial infarction and related cardiac conditions.
✕Less likely to help
People without heart disease or those not at risk for myocardial infarction are unlikely to benefit.
What this research studies
If this research succeeds, it could lead to new ways to limit heart damage within the first day after a heart attack. The project explores how RIPK3 drives cell death in the heart and whether blocking it could spare heart muscle. Researchers may use human cells and animal models to understand the mechanism and test potential interventions. The work aims to identify strategies that could translate into therapies to reduce infarct size and prevent heart failure.
Why it matters
Potential benefit: A potential future therapy could lessen heart damage after a heart attack and lower the risk of heart failure.
How similar studies have gone: Previous studies suggest targeting programmed cell death can protect heart tissue in models of heart attack, but translation to humans remains ongoing.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Kitsis, Richard N — Albert Einstein College of Medicine
- Study coordinator: Kitsis, Richard N
Related research
Other NIH-funded projects on the same topics.
-
Anti-inflammatory signaling of a key protein in heart attack recovery
A study in people who have had a heart attack is exploring how a macrophage protein called Tristetraprolin may reduce inflammation and help protect heart tissue.
-
mRNA lipid nanoparticles to help heart attack patients grow healthier blood vessels
A heart-attack study tests a new treatment that uses messenger RNA delivery with tiny fat bubbles to promote normal blood vessel growth in damaged heart tissue.
-
Targeted nanotherapy to calm inflammation, grow new blood vessels, and prevent scarring after a heart attack
A new treatment approach uses engineered secretions from immune cells delivered early after a heart attack to reduce inflammation, promote blood vessel growth, and limit scarring to protect heart function.
-
Why heart attacks and strokes affect people differently across places and races
This project follows adults across the U.S. to see how lifelong social and neighborhood factors shape heart attacks, heart failure, and recovery, with attention to Black adults and regions with high disease rates.
-
Real-time multi-lead ECG from wearables to help detect heart attacks early
A new AI-based approach uses everyday wearable sensors to turn simple PPG signals into multi-lead ECG data to monitor for heart attacks in real time, even outside the clinic.
-
Extreme heat and heart attack risk: who is most at risk and why
High heat and air pollution may raise the risk of heart attacks, and this project looks at who is most affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.